The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
4-Bromo-N-{3-[5-(2,4,5-trifluoro-3-hydroxybenzoyl)thiophen-2-yl]phenyl}-2-trifluoromethoxybenzenesulfonamide ID: ALA4450585
PubChem CID: 122653011
Max Phase: Preclinical
Molecular Formula: C24H12BrF6NO5S2
Molecular Weight: 652.39
Molecule Type: Unknown
This compound is available for customization.
Associated Items:
Names and Identifiers Canonical SMILES: O=C(c1ccc(-c2cccc(NS(=O)(=O)c3ccc(Br)cc3OC(F)(F)F)c2)s1)c1cc(F)c(F)c(O)c1F
Standard InChI: InChI=1S/C24H12BrF6NO5S2/c25-12-4-7-19(16(9-12)37-24(29,30)31)39(35,36)32-13-3-1-2-11(8-13)17-5-6-18(38-17)22(33)14-10-15(26)21(28)23(34)20(14)27/h1-10,32,34H
Standard InChI Key: WHHDACZXNMFBDX-UHFFFAOYSA-N
Molfile:
RDKit 2D
39 42 0 0 0 0 0 0 0 0999 V2000
18.8532 -12.5468 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
19.5631 -12.1423 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
18.8578 -11.7298 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
15.0506 -11.7378 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.0494 -12.5573 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.7575 -12.9663 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.4671 -12.5569 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.4643 -11.7342 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.7557 -11.3289 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.7533 -10.5118 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.4597 -10.1010 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.0443 -10.1053 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
17.2058 -10.4334 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
17.7508 -9.8245 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.3401 -9.1180 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.5413 -9.2904 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.3414 -12.9654 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
18.5620 -9.9059 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
18.8959 -10.6530 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
19.7081 -10.7362 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.1873 -10.0732 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
19.8485 -9.3249 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
19.0374 -9.2453 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.0423 -11.4819 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
19.8979 -12.8900 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
19.4163 -13.5507 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
19.7499 -14.2959 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.5637 -14.3798 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
21.0427 -13.7125 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.7064 -12.9700 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.3428 -11.3294 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
15.7573 -13.7835 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
17.1755 -12.9643 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
21.1827 -12.3059 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
21.9959 -12.3863 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
22.7366 -12.4574 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
22.4685 -13.0961 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
22.5987 -11.7786 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
20.8989 -15.1251 0.0000 Br 0 0 0 0 0 0 0 0 0 0 0 0
2 1 2 0
3 2 2 0
4 5 2 0
5 6 1 0
6 7 2 0
7 8 1 0
8 9 2 0
9 4 1 0
9 10 1 0
10 11 1 0
10 12 2 0
11 13 1 0
13 14 1 0
14 15 2 0
15 16 1 0
16 11 2 0
5 17 1 0
18 19 2 0
19 20 1 0
20 21 2 0
21 22 1 0
22 23 2 0
23 18 1 0
14 18 1 0
20 24 1 0
24 2 1 0
2 25 1 0
25 26 2 0
26 27 1 0
27 28 2 0
28 29 1 0
29 30 2 0
30 25 1 0
4 31 1 0
6 32 1 0
7 33 1 0
30 34 1 0
34 35 1 0
35 36 1 0
35 37 1 0
35 38 1 0
28 39 1 0
M END Associated Targets(Human) Associated Targets(non-human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 652.39Molecular Weight (Monoisotopic): 650.9244AlogP: 7.23#Rotatable Bonds: 7Polar Surface Area: 92.70Molecular Species: ACIDHBA: 6HBD: 2#RO5 Violations: 2HBA (Lipinski): 6HBD (Lipinski): 2#RO5 Violations (Lipinski): 2CX Acidic pKa: 6.10CX Basic pKa: ┄CX LogP: 7.80CX LogD: 6.13Aromatic Rings: 4Heavy Atoms: 39QED Weighted: 0.12Np Likeness Score: -1.32
References 1. Abdelsamie AS, Herath S, Biskupek Y, Börger C, Siebenbürger L, Salah M, Scheuer C, Marchais-Oberwinkler S, Frotscher M, Pohlemann T, Menger MD, Hartmann RW, Laschke MW, van Koppen CJ.. (2019) Targeted Endocrine Therapy: Design, Synthesis, and Proof-of-Principle of 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibitors in Bone Fracture Healing., 62 (3): [PMID:30645111 ] [10.1021/acs.jmedchem.8b01493 ]